Is Apollomics, Inc. (APLM) a Buy, Sell, or Hold?
Apollomics, Inc.
NASDAQ:APLM
$19.19 USD
$3.49 (22.23%)
- Volume
- 34.21K
- Average Volume
- 15.32K
- Market Capitalization
- $21.17M
- P/E Ratio
- -2.54
- Dividend Yield
- 0.00%
- Price Target
- $
- Year High
- $42.12
- Year Low
- $3.66
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.96
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Hung-Wen Chen |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | APLM |
| CUSIP | G0411D123 |
| CIK | 0001944885 |
| Web | https://www.apollomicsinc.com |
| Phone | 650 209 4055 |
| Currency | USD |
| Employees | 14 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | -0.20 |
| Payout Ratio | 0.00 |
| Current Ratio | 0.96 |
| Quick Ratio | 0.96 |
| Cash Ratio | 0.52 |
Sales & Book Value
| Annual Sales | $8.5M |
| Price / Sales | 2.49 |
| Cash Flow | -6.52 |
| Price / Cash Flow | -7.71 |
| Price / Book | -2.53 |
Price Target and Rating
| Average Stock Price Forecast | $ |
| High Stock Price Forecast | $ |
| Low Stock Price Forecast | $ |
| Forecast Upside/Downside | % |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 2 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-7.57 |
| Trailing P/E Ratio | -2.54 |
| PEG Ratio | -0.02 |
| P/E Growth | -0.02 |
| Net Income | $-10.94M |
| Net Margin | -128.69% |
| Pretax Margin | -128.66% |
| Return on Equity | 288.40% |
| Return on Assets | -162.93% |
Financials Score
| AltmanZ Score | -171.09 |
| Piotroski Score | 3.00 |
| Working Capital | -275K |
| Total Assets | 6.71M |
| Ebit | -50.6M |
| Market Cap | 15.68M |
| Total Liabilities | 9.9M |
Poll Results
About Apollomics, Inc. (NASDAQ:APLM) Stock
Apollomics, Inc., a biotechnology enterprise established in 2015 and headquartered in Foster City, California, conducts its research and development operations across California, Hangzhou, Shanghai, China, and Australia. The company is dedicated to discovering and advancing innovative oncology treatments to address critical unmet medical requirements. Its therapeutic pipeline features APL-101 (Vebreltinib), a potent and selective c-Met inhibitor being developed for non-small cell lung cancer and other advanced malignancies. Also in development is APL-102, an orally administered, small molecule multiple tyrosine kinase inhibitor intended for liver, breast, and esophageal cancers. Furthermore, APL-122 is an investigational tumor inhibitor candidate focused on treating cancers within the brai ... n. The organization was formerly known as CBT Pharmaceuticals, Inc. before adopting the name Apollomics, Inc. in January 2019.
Apollomics Regains Full Compliance with Nasdaq Listing Requirements
2026-07-13 08:00:00
FOSTER CITY, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM ) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced that on July 8, 2026, it received written notice from the Nasdaq Listing Qualifications Staff (Staff) stating that the Company regained compliance with the Market Value of Listed Securities (MVLS) requirement, as set forth in Nasdaq Listing Rule 5550(b)(2) (Rule) for continued listing on the Nasdaq Capital Market, and the matter is now closed.
2026-06-24 16:15:00
FOSTER CITY, Calif., June 24, 2026 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM ) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced that it has received a notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) dated June 18, 2026 stating that the Company is not in compliance with the requirement to maintain a minimum Market Value of Listed Securities (“MVLS”) of $35 million as set forth under Nasdaq Listing Rule for continued listing on The Nasdaq Capital Market.
2026-04-27 08:00:00
Phase 2 studies ongoing to advance global development of vebreltinib, a highly potent, de-risked and differentiated c-MET Inhibitor with best-in-class and first-in-class potential. To date, more than 600 patients and 170 healthy volunteers have been dosed with vebreltinib in clinical trials.
Frequently Asked Questions
-
What is the current Apollomics, Inc. (APLM) stock price?
-
Apollomics, Inc.(NASDAQ:APLM) stock price is $19.19 in the last trading session. During the trading session, APLM stock reached the peak price of $42.12 while $3.659 was the lowest point it dropped to. The percentage change in APLM stock occurred in the recent session was 22.23% while the dollar amount for the price change in APLM stock was $3.49.
-
APLM's industry and sector of operation?
-
The NASDAQ listed APLM is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of APLM?
-
Yi-Kuei Chen | Director & Chief Operating Officer
K. H. Lin | Chief Financial Officer
Hung-Wen Chen | Chief Executive Officer & Chairman of the Board
|
| -
How many employees does APLM have?
-
Number of APLM employees currently stands at 14. APLM operates from 989 East Hillsdale Blvd, Foster City, CA 94404, US.
-
Link for APLM official website?
-
Official Website of APLM is: https://www.apollomicsinc.com
-
How do I contact APLM?
-
APLM could be contacted at phone #650 209 4055 and can also be accessed through its website. APLM operates from 989 East Hillsdale Blvd, Foster City, CA 94404, US.
-
How many shares of APLM are traded daily?
-
The average number of APLM shares traded daily for last 3 months was 15.32K.
-
What is the market cap of APLM currently?
-
The market value of APLM currently stands at $21.17M with its latest stock price at $19.19